Access to Personalized Medicine Drives Utilization of Genomic Tests and Targeted Therapies

4:30 PM - 5:25 PM, Thursday, June 11, 2020 ・ Track Purple (Pacific Time zone listed start time)
Search General Info
Search Education
Search Partnering Companies
Personalized Medicine rests on the assumption that genomic profiling can aid in treatment management decisions, yielding both clinical value for patients and economic value for the system. However, genomic profiling technologies are relatively new and their integration into clinical care has been limited. Our recent analysis relates genomic testing utilization to coverage and access, which has revealed important implications for pharmaceutical, diagnostic, and data platform development, as well as market penetration.

This session will feature a discussion on the patterns of use, coverage, and access to cancer, prenatal, and rare & undiagnosed disease genomic testing across the U.S. Panelists will address and troubleshoot barriers to access, coverage, and clinical implementation of genomic testing and highlight strategic partnerships between biopharma, data providers, and payers that can advance personalized medicine.
Senior Vice President, Science Policy
Personalized Medicine Coalition
Director, Government Affairs, Public Policy & Reimbursement
Medical Director, Medical Affairs Lead
Blue Cross Blue Shield Association
Vice President & Global Head of Market Access
Director, Personalized Medicine and Health Outcomes Research
Nicklaus Children’s Hospital